The DZNE is a research institute within the Helmholtz association that studies neurodegenerative diseases. Its mission is to understand the causes and risk factors that lead to a predisposition for neurodegeneration and to develop new therapeutic and health care strategies. In order to promote high quality research in the field of neurodegeneration, the DZNE closely collaborates with its partner Universities.
DZNE clinical research has the ultimate goal to develop effective therapies for neurodegenerative diseases. This includes translation of novel drug targets from basic research into clinical investigations, trials on relevant, yet unmet needs in patients with manifest disease and promotion of trials on innovative non‐pharmacological interventions. Related to these topics, the DZNE clinical research will focus on improving early and pre‐symptomatic disease detection and course prediction, as the prerequisite for successful development of novel therapies.
Role within Neuromics
Workpackage 1 - Deep phenotype analysis in pre-symptomatic and symptomatic NDD/NMD patients
Workpackage 7 - Omics-based biomarkers for progression and therapy monitoring related to disease pathways
Workpackage 13 - Research infrastructure
Workpackage 2 - Identification of novel disease genes in NDD/NMD patients